Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech is preparing for a pivotal step in the development of its breast cancer drug, pelareorep, by seeking FDA discussions for a registration-enabling trial. The company cites strong data from previous studies that show promise in improving clinical outcomes for HR+/HER2- metastatic breast cancer patients. As Oncolytics Biotech anticipates key survival data and productive FDA discussions in 2024, it marks a potential turning point for the company and its stakeholders.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
